Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK001 vs ampicillin/sulbactam in adult community-acquired pneumonia
CTR20150622Phase 3Active
- Sponsor
- Beijing Rundekang Pharmaceutical Technology
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of AK001 in community-acquired pneumonia (CAP), sponsored by Beijing Rundekang Pharmaceutical Technology. Started Dec 2015; status: active.
02
Drugs
AK001
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on CTR20150622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150622.